Searched for
JB PHARMA PROFIT
Market Trading Guide: Allied Blenders among 2 stock recommendations for FridayDomestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Torrent Pharma shares in focus after CCI clears Rs 19,500 crore acquisition of JB ChemicalsTorrent Pharmaceuticals shares are expected to see activity. The Competition Commission of India has approved Torrent Pharma's plan to acqu...
- Torrent Pharmaceuticals plans Semaglutide rollout post patent expiryTorrent Pharmaceuticals is gearing up to launch both oral and injectable versions of semaglutide, the weight loss drug, following the expir...
- Torrent Pharma to buy controlling stake in JB Chemicals from KKRTorrent Pharmaceuticals is set to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR for ₹11,917 crore, valuin...
- Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuationTorrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will...
- JB Pharma Q3 net profit jumps 22% to Rs 162 croreJB Pharma on Tuesday reported a 22% year-on-year (Y-o-Y) jump in net profit to Rs 162 crore for the quarter ended December 31 led by strong...
- JB Pharma Q2 Results: Net profit jumps 16% to Rs 175 crore, revenue up 13%JB Pharma reported a 16% YoY increase in Q2FY25 net profit to Rs 175 crore, driven by 22% growth in domestic business. Revenues rose 13% to...
- JB Pharma Q1 Results: Net profit jumps 25% YoY to Rs 177 croreThe drug maker had reported a net profit of Rs 142 crore in the year-ago period.Revenue for the quarter rose 12% YoY to Rs 1004 crore
- JB Pharma Q1 Results: Net profit rises 25% YoY to Rs 177 cr"Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the...
- JB Pharma expects India business to grow above market growth rate in FY25: CEO Nikhil ChopraJB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is d...
- JB Pharma Q4 Results: Net profit jumps 43% YoY to Rs 126 croreThe Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up fro...
- JB Pharma Q3 Results: Net profit jumps 26% to Rs 134 croreThe drug maker had reported a net profit of Rs 106 crore in the year-ago period. Revenue for the quarter rose 7% YoY to Rs 845 crore The Mu...
- JB Pharma Q4 Results: Net profit rises 4% to Rs 88 croreOperating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of Indi...
- JB Pharma profit rises 13% to Rs 111 crore in Q2FY23Revenues rose 36% YoY to Rs 809 crore in Q2FY23, compared to Rs 593 crore in Q2FY22.Earnings before interest, depreciation and taxes (EBITD...
- JB Pharma net profit down 12% to Rs 105 croreThe company reported net profit of Rs 119 crore during corresponding period of the previous year.The company attributed the drop in net pro...
- Apax, KKR and PAG in final lap for JB Chemicals buyoutJB Chemicals has a market cap of Rs 5,568 crore. During the last three months, shares of JB Chemicals have gone up 26% on BSE. On Wednesday...
- Lupin, Piramal Healthcare in race for stake in JB ChemicalsPiramal said it does not comment on market speculation, Lupin did not respond to ET’s query.
Load More
